F. Meier

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

C. Garbe, P. Buttner, U. Leiter, 2012, British Journal of Cancer.

Oncogenetics of melanoma: basis for molecular diagnostics and therapy

C. Garbe, M. Röcken, J. Bauer, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients

C. Garbe, G. Rassner, U. Leiter, 2003, Cancer.

Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

D. Elder, P. V. Van Belle, M. Herlyn, 1998, The American journal of pathology.

Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

Incisional biopsy and melanoma prognosis: Facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

Determinants of survival in patients with brain metastases from cutaneous melanoma

C. Garbe, M. Tatagiba, P. Brossart, 2010, British Journal of Cancer.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.

D. Schadendorf, P. Jansen, K. Kähler, 2022, European journal of cancer.

S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Human melanoma progression in skin reconstructs : biological significance of bFGF.

D. Elder, M. Herlyn, C. Garbe, 2000, The American journal of pathology.

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016

F. Meier, O. Schoffer, M. Roessler, 2020, Cancers.

Human Xenografts, Human Skin and Skin Reconstructs for Studies in Melanoma Development and Progression

Carola Berking, Kapaettu Satyamoorthy, C. Berking, 2004, Cancer and Metastasis Reviews.

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.

C. Berking, D. Schadendorf, K. Kähler, 2017, Oncotarget.

E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors.

D. Elder, P. V. Van Belle, M. Herlyn, 2000, The American journal of pathology.

Fibroblast growth factor‐2 but not Mel‐CAM and/or β3 integrin promotes progression of melanocytes to melanoma

C. Berking, M. Herlyn, C. Garbe, 2003, Experimental dermatology.

T-helper-1-cell cytokines drive cancer into senescence

L. Zender, M. Schaller, K. Schulze-Osthoff, 2013, Nature.

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

C. Garbe, G. Pawelec, P. Terheyden, 2021, Journal for ImmunoTherapy of Cancer.

Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies

B. Hutter, B. Brors, M. Ziemer, 2021, Cancer Gene Therapy.

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

B. Maček, K. Ikenberg, C. Garbe, 2016, EBioMedicine.

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Gang Li, Kapaettu Satyamoorthy, Claus Garbe, 2005, Frontiers in bioscience : a journal and virtual library.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

J. Utikal, C. Berking, J. Klode, 2019, European journal of cancer.

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

M. Weichenthal, J. Utikal, D. Schadendorf, 2021, European journal of cancer.

Clinical determinants of long-term survival in metastatic uveal melanoma

M. Weichenthal, J. Utikal, C. Berking, 2021, Cancer Immunology, Immunotherapy.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

C. Berking, D. Schadendorf, B. Schilling, 2016, Clinical Cancer Research.

The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism

P. Friedl, M. Ahmadian, John G. Collard, 2004, Journal of Cell Science.

Systemic Therapy of Metastatic Melanoma: On the Road to Cure

S. Beissert, F. Meier, D. Westphal, 2021, Cancers.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

A. Enk, B. Schilling, Douglas B. Johnson, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

C. Garbe, M. Levesque, C. Krepler, 2017, European journal of cancer.

Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication

M. Herlyn, K. Satyamoorthy, F. Meier, 2001, Oncogene.

Decoding molecular programs in melanoma brain metastases

F. Heppner, T. Redmer, F. Grebien, 2022, Nature Communications.

Patient-specific identification of genome-wide DNA-methylation differences between intracranial and extracranial melanoma metastases

M. Seifert, M. Meinhardt, F. Meier, 2023, Scientific Reports.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

A. Hauschild, D. Schadendorf, J. Taube, 2022, The New England journal of medicine.

ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition

H. Rodemann, F. Meier, M. Toulany, 2014, Cancer biology & therapy.

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

C. Berking, C. Garbe, S. Kimeswenger, 2021, Journal for ImmunoTherapy of Cancer.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

C. Garbe, M. Levesque, C. Krepler, 2017, European journal of cancer.

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

G Rassner, C. Garbe, G. Rassner, 2002, The British journal of dermatology.

PTEN regulates IGF‐1R‐mediated therapy resistance in melanoma

N. Leslie, Jun Wang, B. Schittek, 2015, Pigment cell & melanoma research.

The future of targeted therapy approaches in melanoma

V. Sondak, K. Smalley, F. Meier, 2009, Expert opinion on drug discovery.

Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets

A. Temme, M. Bachmann, F. Meier, 2020, Frontiers in Immunology.

Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.

A. Blum, C. Garbe, G. Rassner, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Costs of the detection of metastases and follow-up examinations in cutaneous melanoma

A. Marghoob, C. Meisner, C. Garbe, 2009, Melanoma research.

Information‐seeking and use of information resources among melanoma patients of German skin cancer centers

C. Berking, D. Schadendorf, W. Tilgen, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.

M. Weichenthal, J. Utikal, S. Haferkamp, 2022, European journal of cancer.

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.

J. Utikal, C. Berking, K. Kähler, 2021, European journal of cancer.

Melanoma brain metastases - Interdisciplinary management recommendations 2020.

D. Schadendorf, R. Gutzmer, D. Vordermark, 2020, Cancer treatment reviews.

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

C. Garbe, F. Meier, T. Sinnberg, 2020, Neuro-oncology advances.

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

J. Utikal, C. Berking, A. Gesierich, 2019, Journal of Immunotherapy for Cancer.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade

C. Garbe, G. Pawelec, P. Terheyden, 2019, PloS one.

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

C. Berking, D. Schadendorf, K. Kähler, 2017, Oncotarget.

Identification of epigenetically regulated genes distinguishing intracranial from extracranial melanoma metastases.

E. Schröck, D. Aust, D. Schrimpf, 2023, The Journal of investigative dermatology.

Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma

A. Linge, E. Troost, F. Meier, 2018, Clinical and translational radiation oncology.

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.

K. Flaherty, C. Garbe, B. Schittek, 2008, The Journal of investigative dermatology.

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2020, The Lancet.

Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers

D. Zillikens, R. Gutzmer, R. Herbst, 2021, Frontiers in Immunology.

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.

Jakob Nikolas Kather, Roman C. Maron, H. Haenssle, 2021, European journal of cancer.

[Targeted therapies for melanoma].

C. Garbe, U. Leiter, F. Meier, 2014, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis

C. Berking, M. Heppt, F. Meier, 2022, JMIR cancer.

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis

C. Garbe, A. Forschner, U. Leiter, 2013, PloS one.

Protein kinase inhibitors in melanoma

C. Garbe, F. Meier, T. Eigentler, 2013, Expert opinion on pharmacotherapy.

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma

C. Garbe, P. Buettner, G. Metzler, 2012, PloS one.

Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.

H. Gollnick, C. Garbe, P. Buettner, 2012, Journal of the American Academy of Dermatology.

Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?

C. Garbe, P. Buettner, A. Forschner, 2010, Melanoma research.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

A. Gesierich, K. Kähler, S. Ugurel, 2017, European journal of cancer.

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.

C. Berking, A. Hauschild, K. Kähler, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

A. Gesierich, K. Kähler, L. Heinzerling, 2018, Cancer Immunology, Immunotherapy.

Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009

C. Garbe, P. Buettner, U. Leiter, 2011, Melanoma research.

Systemic therapy of metastatic melanoma

U. Dietrich, S. Beissert, F. Meier, 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

C. Garbe, D. Schmidt, U. Leiter, 2011, Cancer Immunology, Immunotherapy.

Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement

C. Garbe, P. Buettner, M. Moehrle, 2009, Annals of Surgical Oncology.

Prolonged survival of 2 years or longer for patients with disseminated melanoma

C. Garbe, G. Rassner, F. Meier, 1997, Cancer.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

J. Utikal, C. Berking, A. Gesierich, 2017, European journal of cancer.

In vitro models of melanoma

F. Meier, D. Kulms, 2018 .

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study

M. Weichenthal, S. Haferkamp, D. Schadendorf, 2021, Cancers.

Vemurafenib and ipilimumab: A promising combination? Results of a case series

A. Enk, D. Jäger, A. Dimitrakopoulou-Strauss, 2016, Oncoimmunology.

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2021, Frontiers in Oncology.

Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID‐19

M. Arenbergerova, A. Lallas, K. Peris, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

The role of radiotherapy in the overall treatment of melanoma.

C. Garbe, A. Forschner, F. Meier, 2013, Clinics in dermatology.

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism

C. Praetorius, R. Kontermann, M. Rehm, 2020, Cell Death & Differentiation.

FC12 Long term follow-up of 72 melanoma patients after intratumoral treatment with interleukin-2: favorable survival and high rate of objective responses upon subsequent chemotherapy

C. Garbe, U. Leiter, C. Pföhler, 2010 .

Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial

M. Salzmann, B. Wild, W. Eich, 2021, Trials.

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma

Andreas von Deimling, Jürgen Bauer, Christian Busch, 2014, PloS one.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

D. Schadendorf, K. Flaherty, R. Dummer, 2013, Cancer medicine.

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

C. Berking, D. Schadendorf, B. Schilling, 2021, Cancers.

Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour

C. Garbe, U. Leiter, J. Bauer, 2013, PloS one.

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2022, The Lancet.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma

K. Flaherty, C. Garbe, C. Praetorius, 2017, Clinical Cancer Research.

P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities

er, C. Garbe, P. Buettner, 2010 .

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

J. Utikal, C. Berking, S. Haferkamp, 2017, European journal of cancer.

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study

J. Utikal, C. Berking, M. Ziemer, 2018, Oncotarget.

Melanoma staging: facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis.

M. Herlyn, C. Garbe, U. Weidle, 2004, The Journal of investigative dermatology.

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

M. Weichenthal, S. Haferkamp, K. Kähler, 2020, European Journal of Cancer.

Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.

D. Schadendorf, S. Ugurel, L. Umutlu, 2021, European journal of cancer.

Robustness of convolutional neural networks in recognition of pigmented skin lesions.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, European journal of cancer.

Reciprocal regulation of MelCAM and AKT in human melanoma

M. Herlyn, Gang Li, Xiaowei Xu, 2003, Oncogene.

Characterisation and outcome of RAC1 mutated melanoma.

M. Weichenthal, J. Utikal, D. Schadendorf, 2023, European journal of cancer.

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

C. Berking, D. Schadendorf, B. Schilling, 2021, European journal of cancer.

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.

Jakob Nikolas Kather, J. Utikal, A. Hekler, 2021, European journal of cancer.

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells

K. Flaherty, C. Garbe, C. Zielinski, 2008 .

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

A. Gesierich, K. Kähler, S. Ugurel, 2022, Data in brief.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

J. Utikal, C. Berking, D. Schadendorf, 2018, British Journal of Cancer.

Explainable artificial intelligence in skin cancer recognition: A systematic review.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2022, European journal of cancer.

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

V. Sondak, K. Flaherty, J. Kirkwood, 2015, Cancer discovery.

A benchmark for neural network robustness in skin cancer classification.

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, European Journal of Cancer.

Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review

Jakob Nikolas Kather, R. Maron, J. Utikal, 2021, Journal of medical Internet research.

1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO

M. Weichenthal, J. Utikal, S. Haferkamp, 2020 .

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.

M. Weichenthal, J. Utikal, S. Haferkamp, 2023, European journal of cancer.

Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group.

A. Enk, C. Berking, S. Haferkamp, 2020, European journal of cancer.

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.

L. Hakim-Meibodi, R. Dummer, P. Budde, 2020 .

One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach.

C. Berking, D. Schadendorf, M. Heppt, 2022, Journal of cancer education : the official journal of the American Association for Cancer Education.

Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma

P. Pereira, C. Garbe, C. Sommer, 2018, European Radiology.

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis

M. Weichenthal, J. Utikal, C. Berking, 2021, Cancers.

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

C. Garbe, G. Pawelec, M. Claassen, 2023, Journal for ImmunoTherapy of Cancer.

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

M. Weichenthal, J. Utikal, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)

A. Hauschild, D. Schadendorf, C. Garbe, 2019, Annals of Oncology.

Effects of Label Noise on Deep Learning-Based Skin Cancer Classification

Benjamin Izar, Achim Hekler, Jakob N. Kather, 2020, Frontiers in Medicine.

Using Multiple Dermoscopic Photographs of One Lesion Improves Melanoma Classification via Deep Learning: A Prognostic Diagnostic Accuracy Study

Jakob Nikolas Kather, R. Maron, J. Utikal, 2023, ArXiv.

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world Dermatologic Cooperative Oncology Group study

A. Hauschild, D. Schadendorf, K. Kähler, 2023, European Journal of Cancer.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

J. Utikal, A. Hauschild, S. Haferkamp, 2023, The Lancet.

COVID‐19 and immune checkpoint inhibitors

S. Beissert, F. Meier, L. Reinhardt, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Are YouTube videos on cutaneous squamous cell carcinoma a useful and reliable source for patients?

C. Berking, F. Meier, L. Reinhardt, 2022, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients

C. Berking, D. Schadendorf, W. Tilgen, 2019, Journal of Cancer Education.

Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo

C. Busch, C. Garbe, F. Meier, 2012, Pigment cell & melanoma research.

Lower leg reconstruction after resection of a squamous cell carcinoma on necrobiosis lipoidica with a pedicled fibula and an extended anterolateral thigh flap—a case report

K. Schaser, F. Meier, A. Dragu, 2023, World Journal of Surgical Oncology.

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition

R. Gutzmer, A. Roesch, D. Vordermark, 2023, Cancers.

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

D. Rimm, C. Garbe, M. Röcken, 2023, EBioMedicine.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

German YouTube™ videos as a source of information on cutaneous melanoma: a critical appraisal

C. Berking, F. Meier, L. Reinhardt, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences

C. Berking, D. Schadendorf, W. Tilgen, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment

S. Beissert, M. Meinhardt, F. Meier, 2023, International journal of molecular sciences.

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

J. Utikal, D. Schadendorf, A. Gesierich, 2023, European Journal of Cancer.

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

G. Rassner, B. Schittek, F. Meier, 2002 .

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.

A. Hauschild, D. Schadendorf, L. Heinzerling, 2023, European journal of cancer.

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.

M. Weichenthal, J. Utikal, D. Schadendorf, 2023, Frontiers of medicine.

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

M. Heppt, R. Dummer, L. Heinzerling, 2023, Cancers.